At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 15 target
Drug / intervention
Drugs Nivolumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
In Brief
A Phase 2 clinical trial evaluating Drugs Nivolumab, Ipilimumab, and 1 other intervention for Renal Cell Carcinoma, Clear Cell. Currently recruiting, targeting 15 participants across 6 sites.
Detailed Summary
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and ipilimumab 1mg/kg Q3W IV in first-line advanced RCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Clear Cell
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2Recruiting
20252026202720282029
First PostedNov 2024
Enrollment StartMar 2025
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2028
First PostedNov 29, 2024
Enrollment StartMar 20, 2025
Primary CompletionDec 15, 2026
Study CompletionDec 15, 2028
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 1.6 years agoPrimary completion in 5 months
Interventions
Drugs Nivolumabdrug
Given by IV Infusion
Ipilimumabdrug
Given by IV Infusion
BMS-986213 (Relatlimab-Nivolumab FDC)drug
Given by IV Infusion